Log In
Print
BCIQ
Print
Print this Print this
 

VX-787

  Manage Alerts
Collapse Summary General Information
Company Vertex Pharmaceuticals Inc.
DescriptionOral polymerase inhibitor that directly disrupts replication in influenza A viruses
Molecular Target Viral polymerase
Mechanism of ActionViral polymerase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationInfluenza virus
Indication DetailsTreat influenza A infection
Regulatory Designation

Partner

Johnson & Johnson


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$30.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today